Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05079919




Registration number
NCT05079919
Ethics application status
Date submitted
4/10/2021
Date registered
15/10/2021
Date last updated
6/11/2024

Titles & IDs
Public title
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
Secondary ID [1] 0 0
2021-002192-19
Secondary ID [2] 0 0
ISIS 678354-CS5
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Severe Hypertriglyceridemia 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Olezarsen
Treatment: Drugs - Placebo

Experimental: Olezarsen - Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.

Placebo comparator: Placebo - Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.


Treatment: Drugs: Olezarsen
Olezarsen will be administered by SC injection.

Treatment: Drugs: Placebo
Olezarsen-matching placebo will be administered by SC injection.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percent Change from Baseline in Fasting TG at 6 Months (Average of Weeks 25 and 27) Compared to Placebo
Timepoint [1] 0 0
Baseline and Month 6
Secondary outcome [1] 0 0
Percent Change from Baseline in Fasting TG at 12 Months (Average of Weeks 51 and 53) Compared to Placebo
Timepoint [1] 0 0
Baseline and Month 12
Secondary outcome [2] 0 0
Proportion of Participants Who Achieve Fasting TG Less Than (<) 500 milligrams per deciliter (mg/dL) (5.7 millimoles per liter [mmol/L]) at 6 and 12 Months Compared to Placebo
Timepoint [2] 0 0
Month 6 and 12
Secondary outcome [3] 0 0
Proportion of Participants Who Achieve Fasting TG < 880 mg/dL (10 mmol/L) at 6 and 12 Months Compared to Placebo in the Subgroup of Participants with Baseline TG = 880 mg/dL
Timepoint [3] 0 0
Month 6 and 12
Secondary outcome [4] 0 0
Proportion of Participants Who Achieve Fasting TG < 1000 mg/dL (11.29 mmol/L) at 6 and 12 Months Compared to Placebo in the Subgroup of Participants with Baseline TG = 1000 mg/dL
Timepoint [4] 0 0
Month 6 and Month 12
Secondary outcome [5] 0 0
Percent Change from Baseline in Fasting Apolipoprotein C-III (ApoC-III) at 6 and 12 Months Compared to Placebo
Timepoint [5] 0 0
Baseline, Month 6 and 12
Secondary outcome [6] 0 0
Percent Change from Baseline in Fasting Very Low-Density Lipoprotein Cholesterol (VLDL-C) at 6 and 12 Months Compared to Placebo
Timepoint [6] 0 0
Baseline, Month 6 and 12
Secondary outcome [7] 0 0
Percent Change from Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at 6 and 12 Months Compared to Placebo
Timepoint [7] 0 0
Baseline, Month 6 and 12
Secondary outcome [8] 0 0
Percent Change from Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at 6 and 12 Months Compared to Placebo
Timepoint [8] 0 0
Baseline, Month 6 and 12
Secondary outcome [9] 0 0
Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo, in Participants with = 2 Events of Adjudicated Acute Pancreatitis in 5 Years Prior to Enrollment
Timepoint [9] 0 0
Week 1 through Week 53
Secondary outcome [10] 0 0
Adjudicated Acute Pancreatitis Event Rate from Week 13 to Week 53 Compared to Placebo in Participants with = 2 Events of Adjudicated Acute Pancreatitis in 5 Years Prior to Enrollment
Timepoint [10] 0 0
Week 13 through Week 53
Secondary outcome [11] 0 0
Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo
Timepoint [11] 0 0
Week 1 through Week 53
Secondary outcome [12] 0 0
Adjudicated Acute Pancreatitis Event Rate from Week 13 to Week 53 Compared to Placebo
Timepoint [12] 0 0
Week 13 through Week 53

Eligibility
Key inclusion criteria
Key

* Fasting TG = 500 mg/dL (5.65 mmol/L) at Screening and Qualification
* Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Hemoglobin A1c (HbA1c) = 9.5% at Screening
* Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal
* Total bilirubin > upper limit of normal unless due to Gilbert's syndrome
* Estimated GFR < 30 mL/min/1.73 m^2

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/10/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2025
Actual
Sample size
Target
Accrual to date
Final
617
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Royal North Shoe Hospital - Saint Leonards
Recruitment hospital [3] 0 0
Dr. Heart Pty Ltd at Cholesterol Care Australia - Woolloongabba
Recruitment hospital [4] 0 0
Monash Medical Centre - Clayton S.
Recruitment hospital [5] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [6] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2065 - Saint Leonards
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3168 - Clayton S.
Recruitment postcode(s) [5] 0 0
3004 - Melbourne
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
Nevada
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oklahoma
Country [20] 0 0
United States of America
State/province [20] 0 0
Oregon
Country [21] 0 0
United States of America
State/province [21] 0 0
Rhode Island
Country [22] 0 0
United States of America
State/province [22] 0 0
South Dakota
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
West Virginia
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Blagoevgrad
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Burgas
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Dimitrovgrad
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Gabrovo
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Montana
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Plovdiv
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Ruse
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Sliven
Country [36] 0 0
Bulgaria
State/province [36] 0 0
Smolyan
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Sofia
Country [38] 0 0
Bulgaria
State/province [38] 0 0
Stara Zagora
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Veliko Tarnovo
Country [40] 0 0
Canada
State/province [40] 0 0
British Columbia
Country [41] 0 0
Canada
State/province [41] 0 0
Ontario
Country [42] 0 0
Canada
State/province [42] 0 0
Quebec
Country [43] 0 0
Czechia
State/province [43] 0 0
Brandýs Nad Labem
Country [44] 0 0
Czechia
State/province [44] 0 0
Hradec Králové
Country [45] 0 0
Czechia
State/province [45] 0 0
Náchod
Country [46] 0 0
Czechia
State/province [46] 0 0
Ostrava
Country [47] 0 0
Czechia
State/province [47] 0 0
Prague
Country [48] 0 0
Czechia
State/province [48] 0 0
Uherské Hradište
Country [49] 0 0
Denmark
State/province [49] 0 0
Aalborg
Country [50] 0 0
Denmark
State/province [50] 0 0
Aarhus
Country [51] 0 0
Denmark
State/province [51] 0 0
Esbjerg
Country [52] 0 0
Denmark
State/province [52] 0 0
Frederiksberg
Country [53] 0 0
Denmark
State/province [53] 0 0
Herlev
Country [54] 0 0
Denmark
State/province [54] 0 0
Herning
Country [55] 0 0
Denmark
State/province [55] 0 0
Viborg
Country [56] 0 0
Finland
State/province [56] 0 0
Turku
Country [57] 0 0
Finland
State/province [57] 0 0
Ylitornio
Country [58] 0 0
France
State/province [58] 0 0
Bron
Country [59] 0 0
France
State/province [59] 0 0
Dijon
Country [60] 0 0
France
State/province [60] 0 0
Marseille
Country [61] 0 0
France
State/province [61] 0 0
Montpellier
Country [62] 0 0
France
State/province [62] 0 0
Paris
Country [63] 0 0
France
State/province [63] 0 0
Saint-Herblain
Country [64] 0 0
Germany
State/province [64] 0 0
Berlin
Country [65] 0 0
Germany
State/province [65] 0 0
Dresden
Country [66] 0 0
Germany
State/province [66] 0 0
Hamburg
Country [67] 0 0
Germany
State/province [67] 0 0
Hannover
Country [68] 0 0
Germany
State/province [68] 0 0
Heidelberg
Country [69] 0 0
Germany
State/province [69] 0 0
Köln
Country [70] 0 0
Germany
State/province [70] 0 0
Markkleeberg
Country [71] 0 0
Germany
State/province [71] 0 0
Papenburg
Country [72] 0 0
Germany
State/province [72] 0 0
Witten
Country [73] 0 0
Hungary
State/province [73] 0 0
Heves
Country [74] 0 0
Hungary
State/province [74] 0 0
Szabolcs-Szatmar-Bereg
Country [75] 0 0
Hungary
State/province [75] 0 0
Borsod
Country [76] 0 0
Hungary
State/province [76] 0 0
Budapest
Country [77] 0 0
Hungary
State/province [77] 0 0
Debrecen
Country [78] 0 0
Hungary
State/province [78] 0 0
Miskolc
Country [79] 0 0
Hungary
State/province [79] 0 0
Nyíregyháza
Country [80] 0 0
Hungary
State/province [80] 0 0
Szekesfehervar
Country [81] 0 0
Hungary
State/province [81] 0 0
Veszprém
Country [82] 0 0
Israel
State/province [82] 0 0
Be'er Sheva
Country [83] 0 0
Israel
State/province [83] 0 0
Haifa
Country [84] 0 0
Israel
State/province [84] 0 0
Jerusalem
Country [85] 0 0
Israel
State/province [85] 0 0
Petach Tikva
Country [86] 0 0
Israel
State/province [86] 0 0
Re?ovot
Country [87] 0 0
Israel
State/province [87] 0 0
Tel Aviv
Country [88] 0 0
Israel
State/province [88] 0 0
Tel HaShomer
Country [89] 0 0
Italy
State/province [89] 0 0
Bologna
Country [90] 0 0
Italy
State/province [90] 0 0
Milano
Country [91] 0 0
Italy
State/province [91] 0 0
Napoli
Country [92] 0 0
Italy
State/province [92] 0 0
Palermo
Country [93] 0 0
Italy
State/province [93] 0 0
Roma
Country [94] 0 0
Netherlands
State/province [94] 0 0
Amsterdam
Country [95] 0 0
Netherlands
State/province [95] 0 0
Arnhem
Country [96] 0 0
Netherlands
State/province [96] 0 0
Dordrecht
Country [97] 0 0
Netherlands
State/province [97] 0 0
Ede
Country [98] 0 0
Netherlands
State/province [98] 0 0
Nijmegen
Country [99] 0 0
Netherlands
State/province [99] 0 0
Rotterdam
Country [100] 0 0
Netherlands
State/province [100] 0 0
Utrecht
Country [101] 0 0
New Zealand
State/province [101] 0 0
Auckland
Country [102] 0 0
New Zealand
State/province [102] 0 0
Christchurch
Country [103] 0 0
New Zealand
State/province [103] 0 0
Newtown
Country [104] 0 0
Norway
State/province [104] 0 0
Oslo
Country [105] 0 0
Poland
State/province [105] 0 0
Katowice
Country [106] 0 0
Poland
State/province [106] 0 0
Poznan
Country [107] 0 0
Poland
State/province [107] 0 0
Skierniewice
Country [108] 0 0
Poland
State/province [108] 0 0
Tarnów
Country [109] 0 0
Poland
State/province [109] 0 0
Wroclaw
Country [110] 0 0
Poland
State/province [110] 0 0
Lódz
Country [111] 0 0
Portugal
State/province [111] 0 0
Aveiro
Country [112] 0 0
Portugal
State/province [112] 0 0
Coimbra
Country [113] 0 0
Portugal
State/province [113] 0 0
Lisbon
Country [114] 0 0
Portugal
State/province [114] 0 0
Porto
Country [115] 0 0
Portugal
State/province [115] 0 0
Vila Nova De Gaia
Country [116] 0 0
Slovakia
State/province [116] 0 0
Bratislava
Country [117] 0 0
Slovakia
State/province [117] 0 0
Brezno
Country [118] 0 0
Slovakia
State/province [118] 0 0
Kosice
Country [119] 0 0
Slovakia
State/province [119] 0 0
Košice
Country [120] 0 0
Slovakia
State/province [120] 0 0
Svidnik
Country [121] 0 0
South Africa
State/province [121] 0 0
Free State
Country [122] 0 0
South Africa
State/province [122] 0 0
Gauteng
Country [123] 0 0
South Africa
State/province [123] 0 0
Western Cape
Country [124] 0 0
South Africa
State/province [124] 0 0
Cape Town
Country [125] 0 0
South Africa
State/province [125] 0 0
Chatsworth
Country [126] 0 0
Spain
State/province [126] 0 0
A Coruña
Country [127] 0 0
Spain
State/province [127] 0 0
Barcelona
Country [128] 0 0
Spain
State/province [128] 0 0
Córdoba
Country [129] 0 0
Spain
State/province [129] 0 0
Madrid
Country [130] 0 0
Spain
State/province [130] 0 0
Sevilla
Country [131] 0 0
Spain
State/province [131] 0 0
Tarragona
Country [132] 0 0
Sweden
State/province [132] 0 0
Västra Götalands Län
Country [133] 0 0
Sweden
State/province [133] 0 0
Stockholm
Country [134] 0 0
Turkey
State/province [134] 0 0
Ankara
Country [135] 0 0
Turkey
State/province [135] 0 0
Izmir
Country [136] 0 0
Turkey
State/province [136] 0 0
Kocaeli
Country [137] 0 0
Turkey
State/province [137] 0 0
Konya
Country [138] 0 0
United Kingdom
State/province [138] 0 0
Cornwall
Country [139] 0 0
United Kingdom
State/province [139] 0 0
Dorset
Country [140] 0 0
United Kingdom
State/province [140] 0 0
England
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Huddersfield
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Northamptonshire
Country [143] 0 0
United Kingdom
State/province [143] 0 0
West Bromwich
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Blackpool
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Cornwell
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Glasgow
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Hull
Country [148] 0 0
United Kingdom
State/province [148] 0 0
London
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Manchester
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Preston
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Ionis Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Trial website
https://clinicaltrials.gov/study/NCT05079919
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05079919